ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1262

Efficacy of Statin Use in Patients Undergoing Peritoneal Dialysis

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Kim, Hyung Woo, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Ryu, Geun Woo, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Kang, Shinchan, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Nam, Yooju, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
  • Kim, Beom seok, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (the Republic of)
Background

The efficacy of statin uses in patients with PD have not been proven in large studies. Because most of studies included only HD patients or a small number of PD patients, there is lack of evidence whether statin have positive effect on PD patients or not. The aim of this study was to reveal the efficacy of statin uses in PD patients.

Methods

A total 612 incident PD patients between January 2006 and August 2019 were included in this study. The primary outcome was all-cause mortality and the main exposure of interest was a cumulative dose of statin. For defining the cumulative dose for statin, the definition of defined daily dose by World Health Organization was used. Patients who used statin for at least 28 cumulative defined daily doses (cDDD) after initiation of PD were defined as statin user.

Results

During a median follow-up duration of 33.0 months (IQR, 15.0-63.0), the primary outcome occurred in 124 (20.2%) patients. The mean age at initiation of PD was 53.6±14.5 years and 329 (53.8%) patients were men. The number of statin users was 390 (63.7%) and the number of patients who use statin before starting PD was 311 (50.8%). Statin use (≥28 cDDD) was associated with a lower risk of all-cause mortality (HR, 0.32; 95% CI, 0.20-0.52) after adjustment and this association was also consistent regardless of the use of statin before PD initiation. Adjusted hazard ratios for the all-cause mortality were 0.87 (95% CI, 0.53-1.43), 0.39 (95% CI, 0.20-0.75), 0.41 (95% CI, 0.18-0.91), and 0.13 (95% CI, 0.06-0.26) for the 28-365, 366-730, and 731-1095, respectively, compared with cDDD<28. The risk reduction of statin may be dose dependent.

Conclusion

Statin use was associated with a reduced risk of all-cause mortality in incident PD patients with or without statin use before dialysis.